Research ArticleRadiochemistry
Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression
David J. Donnelly, R. Adam Smith, Paul Morin, Daša Lipovšek, Jochem Gokemeijer, Daniel Cohen, Virginie Lafont, Tritin Tran, Erin L. Cole, Martin Wright, Joonyoung Kim, Adrienne Pena, Daniel Kukral, Douglas D. Dischino, Patrick Chow, Jinping Gan, Olufemi Adelakun, Xi-Tao Wang, Kai Cao, David Leung, Samuel J. Bonacorsi and Wendy Hayes
Journal of Nuclear Medicine March 2018, 59 (3) 529-535; DOI: https://doi.org/10.2967/jnumed.117.199596
David J. Donnelly
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
R. Adam Smith
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Paul Morin
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Daša Lipovšek
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Jochem Gokemeijer
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Daniel Cohen
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Virginie Lafont
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Tritin Tran
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Erin L. Cole
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Martin Wright
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Joonyoung Kim
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Adrienne Pena
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Daniel Kukral
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Douglas D. Dischino
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Patrick Chow
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Jinping Gan
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Olufemi Adelakun
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Xi-Tao Wang
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Kai Cao
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
David Leung
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Samuel J. Bonacorsi Jr.
Bristol-Myers Squibb Research and Development, Princeton, New Jersey
Wendy Hayes
Bristol-Myers Squibb Research and Development, Princeton, New Jersey

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 59, Issue 3
March 1, 2018
Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression
David J. Donnelly, R. Adam Smith, Paul Morin, Daša Lipovšek, Jochem Gokemeijer, Daniel Cohen, Virginie Lafont, Tritin Tran, Erin L. Cole, Martin Wright, Joonyoung Kim, Adrienne Pena, Daniel Kukral, Douglas D. Dischino, Patrick Chow, Jinping Gan, Olufemi Adelakun, Xi-Tao Wang, Kai Cao, David Leung, Samuel J. Bonacorsi, Wendy Hayes
Journal of Nuclear Medicine Mar 2018, 59 (3) 529-535; DOI: 10.2967/jnumed.117.199596
Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression
David J. Donnelly, R. Adam Smith, Paul Morin, Daša Lipovšek, Jochem Gokemeijer, Daniel Cohen, Virginie Lafont, Tritin Tran, Erin L. Cole, Martin Wright, Joonyoung Kim, Adrienne Pena, Daniel Kukral, Douglas D. Dischino, Patrick Chow, Jinping Gan, Olufemi Adelakun, Xi-Tao Wang, Kai Cao, David Leung, Samuel J. Bonacorsi, Wendy Hayes
Journal of Nuclear Medicine Mar 2018, 59 (3) 529-535; DOI: 10.2967/jnumed.117.199596
Jump to section
Related Articles
Cited By...
- Exploiting macropinocytosis for therapeutic intervention in RAS mutant Multiple Myeloma
- Preclinical Evaluation and Pilot Clinical Study of CD137 PET Radiotracer for Noninvasive Monitoring Early Responses of Immunotherapy
- Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer
- Use of Phage Display and Other Molecular Display Methods for the Development of Monobodies
- Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients
- Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of 89Zr-Labeled Anti-PD-L1 Antibody Formats
- Imaging PD-L1 Expression in Melanoma Brain Metastases
- 18F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study
- First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients
- Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics
- Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression
- Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer 18F-BMS-986192
- 89Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
- Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer
- Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?
- The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
- JHU-2545 Selectively Shields Salivary Glands and Kidneys during PSMA-Targeted Radiotherapy
- PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody
- Toward Independent Nuclear Medicine, Molecular Imaging, and Theranostic Programs
- A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1: Validation in Mouse Models and Human Cancer Tissues
- The Immunoimaging Toolbox
- Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology